Bambusa Therapeutics

Bambusa Therapeutics (Ticker: BBTX US) develops long-acting bispecific antibodies for immunology and inflammatory diseases. Its medicines are designed to combine activity across biological pathways and are formulated for high-concentration delivery under the skin. Founded in 2024, the company acquired assets from BioNTech (Zhuhai) Pharmaceuticals R&D that became its lead candidates, BBT001 and BBT002.

BBT001 is being studied for moderate-to-severe atopic dermatitis in global Phase 1 and China Phase 1a/1b trials. It is also being studied for chronic spontaneous urticaria in a China Phase 2a trial. Bambusa is developing BBT003 for inflammatory bowel disease and other gastrointestinal conditions, and BBT004 for autoimmune diseases driven by autoantibodies.

Bambusa Therapeutics expects to begin trading on Nasdaq on October 30, 2026. The proposed offering comprises 9,375,000 shares at an indicative price of $15.00–$17.00 per share. At the indicative midpoint, the base offering would represent approximately $150.00 million in gross proceeds. Estimated IPO market capitalization is $796.19 million. Underwriters include BofA Securities, UBS Investment Bank and Evercore ISI.